• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Current Problems in Cancer >Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcoma
【24h】

Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcoma

机译：Ifosfamide和多柔比星治疗先进的Leiomyosarcoma

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Leiomyosarcomas (LMS) are rare tumors with poor prognosis owing to the high rate of recurrent and metastatic disease. The combination of doxorubicin (Adriamycin) plus ifosfamide and mesna (AIM) results in moderate response rates of 10%-30%. The aim of this study was to assess the efficacy of the AIM regimen along with multimodality treatment including surgery and radiotherapy in patients with LMS. The clinicopathologic characteristics and outcomes of 51 patients with recurrent or metastatic LMS diagnosed between 2000 and 2014 who received the AIM regimen were analyzed retrospectively. Treatment consisted of ifosfamide 2500mg/m2 on days 1-3 (with mesna 2500mg/m2 days 1-3, 4-hour i.v. infusion), and doxorubicin 60mg/m2 on day 1 (2-hour i.v. infusion), which was repeated every 21 days. The mean age of the patients at diagnosis was 48.9 ± 11.2 years. A total of 42 patients were females (82.4%). The primary tumor site was the uterus in 30 (58.8%) patients. The most common metastatic sites were lung and liver. The median follow-up was 27.9 months (min: 4.3 max: 164.8). The median progression-free survival was 6.7 months (95% CI: 4.1-9.2). The median overall survival (OS) was 24.6 months (95% CI: 16.2-33.0). The overall response rate was 12% (6/51 pts). Response rates were higher in patients with uterine LMS (17%) compared with those with nonuterine LMS (5%); however, the OS times were similar. Surgical intervention for local or distant recurrence was associated with improved median OS (41 vs 16.6 months,P< 0.001). Myelosuppression was the major toxicity of this combination. In our study, the AIM regimen was effective in patients with LMS. Resection of local or distant recurrence was found to improve survival in our study.
机译：Leiomyosarcomas（LMS）是由于经常性和转移性疾病的高速率罕见的预后罕见肿瘤。多柔比星（Adriamycin）加IfOsfamide和Mesna（AIM）的组合导致中等反应率为10％-30％。本研究的目的是评估AIM方案的疗效以及多律治疗，包括LMS患者的手术和放疗。回顾性地分析了2000年至2014年在2000和2014年间诊断的51例复发性或转移性LMS患者的临床病理特征和结果。在第1-3天（MESNA 2500mg / m 2天1-3，4小时IV输注）和第1天（2小时IV输注）中的二十次（4小时静脉注射）组成的治疗组成21天。诊断患者的平均年龄为48.9±11.2岁。共有42名患者是女性（82.4％）。主要肿瘤部位是30（58.8％）患者的子宫。最常见的转移性位点是肺和肝。中位后续时间为27.9个月（最小：4.3 Max：164.8）。中位进展生存期为6.7个月（95％CI：4.1-9.2）。中位数总存活（OS）为24.6个月（95％CI：16.2-33.0）。整体反应率为12％（6/51分）。与壬嗪LMS（5％）相比，子宫LMS（17％）患者的反应率较高（17％）;但是，OS时间相似。对局部或远程复发的手术干预与改善的中值OS（41 vs 16.6个月，P <0.001）有关。骨髓抑制是这种组合的主要毒性。在我们的研究中，AIM方案在LMS患者中有效。发现局部或远程复发的切除改善我们研究中的生存。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号